NAD+ appears in discussions about energy, aging, and an expanding range of wellness products. Before deciding what to make of those offers, it helps to understand the smaller, more precise statement underneath them: NAD is a coenzyme involved in essential cellular chemistry.
That biological role explains scientific interest. It does not, by itself, establish that buying more of a substance improves a person’s health. The interesting work begins when a study tests a particular intervention, in particular people, against a meaningful comparison.
THE USEFUL DISTINCTION
A molecule can be essential to normal biology without every product bearing its name having proven clinical benefits.
What the plus sign belongs to
Nicotinamide adenine dinucleotide participates in oxidation-reduction reactions central to metabolism. NAD+ and NADH describe related forms involved in those reactions. The body makes and recycles NAD through pathways connected with nutrients including niacin.
This is background biochemistry, not a diagnosis that tiredness means a person needs an NAD+ injection. Persistent or unexplained symptoms deserve a clinical assessment. Our molecule comparison separates NAD+ from two precursors that often appear in the same advertisements.
Evidence: NIH ODS: niacin and NAD metabolism
How a study narrows the question
An oral nicotinamide riboside study can test changes in blood NAD-related measurements under its protocol. A small intravenous NAD+ study can describe what happens to plasma and urine metabolites after an infusion. These are different experiments, even when both appear under an NAD headline.
The evidence explorer puts three examples side by side. Look at the formulation, participants, duration, control group, and measured outcome before deciding what a result means for a product you are considering.
Evidence: Martens et al.: 2018 oral NR crossover trial / Grant et al.: 2019 IV NAD+ metabolome pilot
A biomarker is not the whole experience
A higher laboratory measurement is not automatically proof of better concentration, less fatigue, or a longer life. Researchers need appropriate clinical endpoints and study designs to test those claims. Short follow-up also limits what can be said about sustained benefit or long-term safety.
Some precursor research does examine clinical function in defined populations. That specificity matters: a condition-specific oral NR result should not become a blanket claim for injectable NAD+ in otherwise healthy adults.
Evidence: McDermott et al.: 2024 NICE trial / Dellinger et al.: 2017 NRPT randomized trial
Bring the product back into view
Ask what exactly is being sold, what evidence matches it, and what the risks and costs are. A compounded injection raises preparation and sterility questions that an oral supplement trial cannot answer.
Read the safety explainer, route comparison, and offer reviews together. The purpose is to make a clinical conversation more informed, not to turn an appealing cellular story into a prescription decision.
Evidence: FDA: suitable ingredients for sterile compounding / FDA: compounding and approval
Open the source material
- NIH ODS: niacin and NAD metabolism
Nutritional and biochemical background, not evidence that a commercial NAD intervention improves longevity.
- Martens et al.: 2018 oral NR crossover trial
Small, short-duration human study of oral NR; cannot establish effectiveness of injectable NAD+.
- Grant et al.: 2019 IV NAD+ metabolome pilot
Eight NAD+ recipients and three saline controls; short-term metabolite measurements, not a longevity or clinical efficacy trial.
- McDermott et al.: 2024 NICE trial
Randomized trial in peripheral artery disease. A condition-specific oral NR result is not general proof for all NAD products.
- Dellinger et al.: 2017 NRPT randomized trial
120 adults aged 60–80, eight weeks; NAD+ biomarker and safety outcomes. Elysium funded the study; not evidence of longer life.
- FDA: suitable ingredients for sterile compounding
Specific NAD+ safety communication: food-grade material, contamination risk and reported adverse events.
- FDA: compounding and approval
Compounded drugs are not FDA-approved; ingredient evidence does not certify the finished preparation.
